Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Riassunto: BeOne Medicines annuncia i nuovi dati sulla sopravvivenza di Fase 3 a supporto del beneficio dei regimi a base di ZIIHERA nel trattamento di prima linea dei tumori gastroesofagei (GEA) HER2-positivi

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines announced positive preliminary results from the Phase 3 HERIZON-GEA-01 study. The trial evaluates ZIIHERA (zanidatamab) combined with chemotherapy, with or without TEVIMBRA (tislelizumab), for first-line treatment of locally advanced HER2-positive gastroesophageal adenocarcinoma. These results support the potential benefits of ZIIHERA in this patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive preliminary results from Phase 3 study.
  • ZIIHERA shows potential effectiveness in treating HER2-positive GEA.
  • Combination therapy may enhance treatment outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha reso noti i risultati preliminari positivi dalla seconda analisi intermedia (IA2) dello studio clinico di Fase 3 HERIZON-GEA-01 volto a valutare l'efficacia di ZIIHERA® (zanidatamab), in associazione con chemioterapia, con e senza TEVIMBRA® (tislelizumab), come trattamento di prima linea dell'adenocarcinoma gastroesofageo (GEA) HER2-positivi localmente avanzato

Frequently Asked Questions

What is ZIIHERA used for?

ZIIHERA (zanidatamab) is evaluated for treating HER2-positive gastroesophageal adenocarcinoma.

What were the results of the Phase 3 study?

The Phase 3 study showed positive preliminary results for ZIIHERA in combination therapies.

What is the significance of the HERIZON-GEA-01 study?

The HERIZON-GEA-01 study assesses the effectiveness of ZIIHERA for first-line GEA treatment.

What other drug is ZIIHERA combined with in the study?

ZIIHERA is combined with chemotherapy and may also include TEVIMBRA (tislelizumab).

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines ZIIHERA HER2-positive GEA oncology
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →